P
Paul de Souza
Researcher at University of Sydney
Publications - 166
Citations - 11818
Paul de Souza is an academic researcher from University of Sydney. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 38, co-authored 150 publications receiving 9924 citations. Previous affiliations of Paul de Souza include Eli Lilly and Company & University of Western Sydney.
Papers
More filters
Journal ArticleDOI
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan,Matthew R. Smith,Johann S. de Bono,Arturo Molina,Christopher J. Logothetis,Paul de Souza,Karim Fizazi,Paul N. Mainwaring,Josep M. Piulats,Siobhan Ng,Joan Carles,Peter F.A. Mulders,Ethan Basch,Eric J. Small,Fred Saad,D. Schrijvers,Hendrik Van Poppel,Som D. Mukherjee,Henrik Suttmann,Winald R. Gerritsen,Thomas W. Flaig,Daniel J. George,Evan Y. Yu,Eleni Efstathiou,Allan J. Pantuck,Eric Winquist,Celestia S. Higano,Mary-Ellen Taplin,Youn C. Park,Thian Kheoh,Thomas W. Griffin,Howard I. Scher,Dana E. Rathkopf +32 more
TL;DR: Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,David Cella,James Reeves,Robert E. Hawkins,Jun Guo,Paul Nathan,Michael Staehler,Paul de Souza,Jaime R. Merchan,Ekaterini Boleti,Kate Fife,Jie Jin,Robert Jones,Hirotsugu Uemura,Ugo De Giorgi,Ulrika Harmenberg,Jinwan Wang,Cora N. Sternberg,Keith C. Deen,Lauren McCann,Michelle D. Hackshaw,Rocco Crescenzo,Lini Pandite,Toni K. Choueiri +24 more
TL;DR: Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazoSmithKline Pharmaceuticals.
Journal ArticleDOI
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan,Matthew R. Smith,Karim Fizazi,Fred Saad,Peter F.A. Mulders,Cora N. Sternberg,Kurt Miller,Christopher J. Logothetis,Neal D. Shore,Eric J. Small,Joan Carles,Thomas W. Flaig,Mary-Ellen Taplin,Celestia S. Higano,Paul de Souza,Johann S. de Bono,Thomas W. Griffin,Peter De Porre,Margaret K. Yu,Youn C. Park,Jinhui Li,Thian Kheoh,V. Naini,Arturo Molina,Dana E. Rathkopf +24 more
TL;DR: Treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant, and further support the favourable safety profile of abiraton acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Lee S. Rosen,David Gordon,Simon Tchekmedyian,Ronald Yanagihara,Vera Hirsh,Maciej Krzakowski,Marek Pawlicki,Paul de Souza,Ming Zheng,Gladys Urbanowitz,Dirk J. Reitsma,John J. Seaman +11 more
TL;DR: Zoledronic acid (4 mg infused over 15 minutes) is the first bisphosphonate to reduce skeletal complications in patients with bone metastases from solid tumors other than breast and prostate cancer.
Journal ArticleDOI
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon,Alba A. Brandes,Antonio Omuro,Paul Mulholland,Michael Lim,Antje Wick,Joachim M. Baehring,Manmeet Ahluwalia,Patrick Roth,Oliver Bähr,Surasak Phuphanich,Juan Manuel Sepúlveda,Paul de Souza,Solmaz Sahebjam,Michael Carleton,Kay Tatsuoka,Corina Taitt,Ricardo Zwirtes,John Sampson,Michael Weller +19 more
TL;DR: Nivolumab monotherapy did not improve overall survival compared with bevacizumab in the treatment of recurrent glioblastoma, and additional research is needed to find out why.